In a subgroup analysis of people living with HIV enrolled in PRIOH-1, pritelivir demonstrated superior lesion healing, achieving 61% complete ...

The presentations can be found on the Posters & Presentations section of the Aligos website ( www.aligos.com) after the live event.

At CROI 2026, experts warned that missing HBV screening risks reactivation during HIV therapy switches.

Data from two studies presented at the Conference on Retroviruses and Opportunistic Infections support the use of a novel, ...

SEATTLE — The genetic vulnerability to psoriasis and related autoimmune diseases may be traceable to evolutionary pressure to resist ancient infections by retroviruses. The theory is that variations ...

DENVER — Pritelivir, an investigational antiviral drug for herpes simplex virus, demonstrated “superior efficacy” in healing lesions in immunocompromised patients, according to results of a phase 3 ...

The combination of doravirine plus islatravir was noninferior to bictegravir/emtricitabine/tenofovir alafenamide and oral antiretroviral therapy in patients who ...

At the 2026 Conference on Retroviruses and Opportunistic Infections, Gilead and Merck demonstrated that their respective daily oral HIV drugs can match current therapies in keeping the virus at bay.

Joint Research Center for Human Retrovirus Infection has the following research output in the current window (1 November 2024 - 31 October 2025) of the Nature Index. Click on Count to view a list of ...

The massive cuts to science, global health, and HIV programs that unfolded in 2025 triggered a crisis with worldwide repercussions. The dissolution of USAID, the shutdown of PEPFAR, and the suspension ...

Scientists in Japan have discovered a genetic "silencer" within the HTLV-1 virus that helps it stay hidden in the body, evading the immune system for decades. This silencer element essentially turns ...